Univercells Technologies

home / authors / univercells-technologies

Articles

AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor

June 21st 2023

In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.

From Tech Transfer to Commercial Scale Viral Manufacturing in 8 months - a CDMO Case Study

Univercells Technologies

May 3rd 2023

Webinar Date/Time: Thu, Jun 1, 2023 11:00 AM EDT

Lentivirus production study in the scale-X™ fixed-bed bioreactor

Univercells Technologies

April 24th 2023

This study aims to evaluate harvest strategies and metabolite-based cell density estimation methods for Lentivirus production with HEK293T cells.

AAV manufacturing: reaching high capacity with serum-free, scalable production

Univercells Technologies

March 3rd 2023

Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT

Simplifying Seed Train: A Benchtop System for Intensified Inoculation of Large-Scale Bioreactors

Univercells Technologies

December 22nd 2022

Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST

Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)

Univercells Technologies

November 17th 2022

This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.

How to Find Success with Lentiviral Production Using Fixed Bed Bioreactor Technology

Univercells Technologies

October 17th 2022

Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST Why would a CDMO to leverage fixed-bed bioreactor technology to develop and produce GMP lentiviral vectors? Join us for a discussion on increasing quality and decreasing time and cost to accelerate time to clinic and market for lentiviral products with technology.

Scalable rubella production in scale-X™ bioreactor with MRC-5 cells

Univercells Technologies

October 14th 2022

This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.